SREBF2 and posterior cortical atrophy: Statins that inhibit HMGCR enzyme in the mevalonate (MVA) pathway and thus interfere with CHOL biosynthesis activate feedback loop involving SREBP2 and lessen the efficacy of statins in PCa [31] but a combination of statin (Fluvastatin) and GAL is reported to inhibit CRPC in vivo by preventing the activation of SREBP2 and the consequential restorative feedback loop [32].